GeneDx Holdings Corp. (WGS)
$64.96+1.79%Close
SELLCRISIS · day 15
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV45.6%–201.3%
- Market cap
- $1.9B
- Beta
- 1.97
- P/E (TTM)
- -17.85
- IV-%ile
- 36
- IV ATM
- 73.4%
- Short % float
- 20.53%
- Days to cover
- 6.0
- SI change
- -4.4%
- 1W
- -9.17%
- 1M
- -27.61%
- vs SPY 1W
- -9.03%
- vs SPY 1M
- -30.12%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 35
- VALUE
- 11
- GROWTH
- 34
- GARP
- 63
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC-23.2%
REV YoY-
ROE-38.7%
EPS YoY-
ROA-22.1%
GROSS68
OP-13
NET-23
[VALUATION]
P/E TTM-17.85
P/E FWD61.34
SECTOR PE20.34
INDUSTRY PE31.41
P/B7.90
P/FCF-
EV/EBITDA-26.75
EV/EBIT-
PEG0.99
FCF YIELD-
RISK
INT COV-
D/E68.55
ALTMAN Z-
CURR RATIO3.30
ND/EBITDA-
BETA1.97
Company news
FAQ
- What is LOPJLB’s current signal on WGS?
- LOPJLB’s latest quantitative signal on GeneDx Holdings Corp. (WGS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is WGS in?
- GeneDx Holdings Corp. (WGS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does GeneDx Holdings Corp. (WGS) do?
- GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and c…